1 Min Read
Dec 19 (Reuters) - Pfizer Inc:
* U.S. FDA APPROVES PFIZER’S BOSULIF® (BOSUTINIB) FOR THE TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.